braf v600e
Entity, reached from Hormuz.
- Evidence
- 41 documents · 16 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 2 Apr 2026, last seen 7 Oct 2026
- Measured
- 15% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- Anticancer Drugs · 2026-09-30 · Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case r… (opens the source in a new tab)
- Annals of Oncology · 2026-09-13 · A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3 (opens the source in a new tab)
- Clinical Colorectal Cancer · 2026-09-11 · Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A … (opens the source in a new tab)
- crc-digest · 2026-09-03 · Real-World Data on Encorafenib Plus Panitumumab in BRAF V600E Metastatic CRC (opens the source in a new tab)
- Clin Colorectal Cancer · 2026-09-02 · Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer. (opens the source in a new tab)
- crc-digest · 2026-08-25 · Cost-effectiveness of triplet therapy for BRAF V600E-mutated metastatic CRC in China (opens the source in a new tab)
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with braf (41 documents)seen together
- co-mentioned with colorectal cancer (29 documents)seen together
- co-mentioned with egfr (10 documents)seen together
- co-mentioned with immunotherapy (10 documents)seen together
- co-mentioned with kras (8 documents)seen together